Liraglutide and cardiovascular outcomes in type 2 diabetes - The New England Journal of Medicine - 2016
Brief Summary:
Among patients with T2DM at increased risk for CVD, liraglutide was associated with a reduction in CV events when compared to placebo.Reference: http://www.ncbi.nlm.nih.gov/pubmed/27295427
Comments
Post a Comment
Drop your thoughts here, we would love to hear from you